MedTrace Logo

Alpha Lipoic Acid Against Cardiovascular Events in Patients With Haemodialysis

NCT03912727 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-12-26

No results posted yet for this study

Summary

Evaluate the association between possible benefit effects of oral administration of alpha lipoic acid by patients with hemodialysis and the possible reduction in cardiovascular events (CVEs); using Advanced glycation end products (AGEs) as a measure to assess endothelium function which correlate with CVEs.

Conditions

  • Hemodialysis Complication

Interventions

DIETARY_SUPPLEMENT

Alpha-Lipoic acid plus renal replacement therapy

Alpha lipoic acid (ALA) is a vitamin-like antioxidant

OTHER

renal replacement therapy

standard renal replacement therapy

Sponsors & Collaborators

  • Al-Azhar University

    collaborator OTHER

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Zeinab A Zalat, Ass. Prof. · Al-Azhar University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-11
Primary Completion
2019-08-30
Completion
2019-09-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03912727 on ClinicalTrials.gov